Skip to main content
Premium Trial:

Request an Annual Quote

EMD Biosciences to Market siRNA, DNA Transfection Reagents from DNT

NEW YORK (GenomeWeb News) – EMD Biosciences, part of Merck KGaA’s Performance and Life Science Chemicals division, has signed an exclusive license and supply agreement with Dendritic Nanotechnologies for siRNA and DNA transfection reagents, the companies said today.
Under the terms of the agreement, DNT a US subsidiary of Australian firm Starpharma, will supply EMD Biosciences with its Priofect transfection reagents. EMD will market the reagents through its Novagen product line.
DNT retains full rights to all in vivo aspects of transfecting nucleic acids with the Priostar technology. Additional terms of the agreement, which includes royalties and milestone payments, were not disclosed.
According to DNT, PrioFect transfection reagents offer nanometer-size control, which will enable EMD to offer siRNA transfection reagents with sizes optimized for individual cell lines.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.